课题基金 / 基金详情

SFB 824: Imaging for Selection, Monitoring and Individualisation of Cancer Therapies

SFB 824: Imaging for Selection, Monitoring and Individualisation of Cancer Therapies
SFB 824:用于癌症治疗选择、监测和个体化的成像
批准号:
68647618
负责人:
金额:
$0.0万
依托单位国家:
德国
项目类别:
Collaborative Research Centres
财政年份:
2009
资助国家:
德国
项目状态:
已结题
起止时间:
2008-12-31 至 2020-12-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
合作研究中心824(SFB824,http://www.sfb824.de))由来自自然科学、生物和临床科学的研究人员组成,位于慕尼黑大学--慕尼黑工业大学(TUM)和路德维希·马克西米连大学(LMU)--以及慕尼黑亥姆霍兹中心大学。SFB 824于2008年7月首次获得资助,目前已进入第7个资助年度。这个跨学科研究平台的首要目标是开发、验证、转换并最终应用尖端成像方法,这些方法改进、替代甚至创建新的成像方法,用于癌症患者的早期诊断、个性化治疗分层和治疗效果监测。近年来,癌症分子特征的重大进展为对抗致命疾病的新的分子定制治疗策略带来了希望。然而,尽管在临床前模型方面取得了令人印象深刻的成功,但对有希望的新药物和治疗方式的临床反应一直是不同的。需要技术来确定可能从针对特定路径或生物模式的选定疗法中受益的患者亚群,并指导和监测治疗策略,这是公认的,对于全球宣传的精确医学概念来说,这是绝对必要的。SFB 824的重点是通过在临床前肿瘤模型中开发和验证新的成像策略来应对这一挑战,旨在快速转化为临床环境。目前的SFB 824申请包括19个单独的项目,这些项目被嵌入三个相互关联的研究包中,集中在(1)引入新的成像方法和成像生物标记物,(2)识别的分子成像靶点的临床前和临床验证,以及(3)用于监测癌症治疗效果的成像方式的应用。SFB 824是TUM核心研究战略的一部分,专注于将生物工程作为跨学科研究的发展平台,从而产生创新的诊断和治疗方法并将其转化为临床应用。为此,该联盟还将并入新的中央转化性癌症研究所(TranslaTUM),这是一座新的研究大楼,提供跨学科的研究环境。
英文摘要
The Collaborative Research Centre 824 (SFB 824, http://www.sfb824.de) constitutes a consortium of researchers from natural sciences, biology and clinical sciences, located at both Munich Universities – Technical University of Munich (TUM) and Ludwig Maximilian University (LMU) – as well as at the Helmholtz-Zentrum Munich (HMGU). The SFB 824 was first funded in July 2008 and is now in its 7th funding year. The overriding aim of this interdisciplinary research platform is to develop, validate, translate and ultimately apply cutting-edge imaging methods, which improve, substitute or even create new imaging approaches for early diagnosis, personalized therapeutic stratification and for monitoring of therapy effects in patients with cancer. In recent years, major advances in the molecular characterization of cancer have raised hopes for new molecularly tailored therapeutic strategies in the fight against deadly diseases. However, despite impressive success in preclinical models, clinical response to promising new agents and treatment modalities has been heterogeneous. The need for technologies to identify subgroups of patients likely to benefit from selected therapies targeting specific pathways or biological modalities and to guide and monitor treatment strategies is well recognized and absolutely fundamental for the worldwide advertised concept of precision medicine. Focus of SFB 824 is to meet this challenge by developing and validating new imaging strategies in preclinical tumor models aiming at fast translation into clinical settings. The current SFB 824 application consists of 19 individual projects, which are embedded in three interconnected research packages concentrating on (1) the introduction of new imaging methodology and imaging biomarkers, (2) the preclinical and clinical validation of identified molecular imaging targets and (3) the application of imaging modalities for monitoring effects of cancer therapeutics. SFB 824 is part of the core research strategy of TUM focusing on bioengineering as developmental platform for interdisciplinary research resulting in innovative diagnostic and therapeutic methods and their translation into clinical application. To this end, the consortium will also be integrated into the new Central Institute for Translational Cancer Research (TranslaTUM), a new research building providing an interdisciplinary research environment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
miR824/AGL16模块对拟南芥TPS7/TPS8的分子调控及其生物学效应
  • 批准号:
    31700275
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2017
  • 负责人:
    董殷鑫
  • 依托单位: